189 related articles for article (PubMed ID: 35843374)
1. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
Allen AM; Therneau TM; Ahmed OT; Gidener T; Mara KC; Larson JJ; Canning RE; Benson JT; Kamath PS
J Hepatol; 2022 Nov; 77(5):1237-1245. PubMed ID: 35843374
[TBL] [Abstract][Full Text] [Related]
2. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.
Komolafe O; Buzzetti E; Linden A; Best LM; Madden AM; Roberts D; Chase TJ; Fritche D; Freeman SC; Cooper NJ; Sutton AJ; Milne EJ; Wright K; Pavlov CS; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013157. PubMed ID: 34280304
[TBL] [Abstract][Full Text] [Related]
3. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
Calzadilla-Bertot L; Vilar-Gomez E; Wong VW; Romero-Gomez M; Aller-de la Fuente R; Wong GL; Castellanos M; Eslam M; Desai AP; Jeffrey GP; George J; Chalasani N; Adams LA
Hepatology; 2021 Jun; 73(6):2238-2250. PubMed ID: 32978796
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
[TBL] [Abstract][Full Text] [Related]
5. High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study.
Bassegoda O; Rivera-Esteban J; Serra I; Morillas R; Broquetas T; Vergara M; Rodriguez A; Aracil C; Virolés S; Carrión JA; Pardo A; Rodríguez-Tajes S; Serra-Burriel M; Pericàs JM; Augustin S; Ginès P; Graupera I
Hepatol Commun; 2022 Nov; 6(11):3212-3222. PubMed ID: 36073343
[TBL] [Abstract][Full Text] [Related]
6. Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.
Buzzetti E; Linden A; Best LM; Madden AM; Roberts D; Chase TJG; Freeman SC; Cooper NJ; Sutton AJ; Fritche D; Milne EJ; Wright K; Pavlov CS; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD013156. PubMed ID: 34114650
[TBL] [Abstract][Full Text] [Related]
7. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States.
Nyberg LM; Cheetham TC; Patton HM; Yang SJ; Chiang KM; Caparosa SL; Stern JA; Nyberg AH
Hepatol Commun; 2021 Jan; 5(1):83-96. PubMed ID: 33437903
[TBL] [Abstract][Full Text] [Related]
8. Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis.
Navadurong H; Thanapirom K; Wejnaruemarn S; Prasoppokakorn T; Chaiteerakij R; Komolmit P; Treeprasertsuk S
World J Gastroenterol; 2023 Aug; 29(32):4873-4882. PubMed ID: 37701131
[TBL] [Abstract][Full Text] [Related]
9. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
10. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
11. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
12. Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD.
Gidener T; Ahmed OT; Larson JJ; Mara KC; Therneau TM; Venkatesh SK; Ehman RL; Yin M; Allen AM
Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1915-1924.e6. PubMed ID: 33010409
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.
Petta S; Sebastiani G; Bugianesi E; Viganò M; Wong VW; Berzigotti A; Fracanzani AL; Anstee QM; Marra F; Barbara M; Calvaruso V; Cammà C; Di Marco V; Craxì A; de Ledinghen V
J Hepatol; 2018 Oct; 69(4):878-885. PubMed ID: 29802949
[TBL] [Abstract][Full Text] [Related]
14. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
[TBL] [Abstract][Full Text] [Related]
15. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis.
Orman ES; Roberts A; Ghabril M; Nephew L; Desai AP; Patidar K; Chalasani N
JAMA Netw Open; 2019 Jun; 2(6):e196412. PubMed ID: 31251379
[TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.
Huang DQ; Noureddin N; Ajmera V; Amangurbanova M; Bettencourt R; Truong E; Gidener T; Siddiqi H; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Yoneda M; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Allen AM; Noureddin M; Loomba R
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):829-836. PubMed ID: 37419133
[TBL] [Abstract][Full Text] [Related]
17. Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria.
Jindal A; Sharma S; Agarwal S; Kumar M; Saraya A; Sarin SK
Hepatol Int; 2022 Feb; 16(1):89-98. PubMed ID: 35072932
[TBL] [Abstract][Full Text] [Related]
18. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
[TBL] [Abstract][Full Text] [Related]
19. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
20. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event.
Balcar L; Tonon M; Semmler G; Calvino V; Hartl L; Incicco S; Jachs M; Bauer D; Hofer BS; Gambino CG; Accetta A; Brocca A; Trauner M; Mandorfer M; Piano S; Reiberger T;
JHEP Rep; 2022 Aug; 4(8):100513. PubMed ID: 35845294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
